Filing Flows › Ionis Pharmaceuticals (IONS) › Q3 2026 › vs Q2 2026
Ionis Pharmaceuticals (IONS) Q3 2026 vs Q2 2026 (quarter over quarter)
Ionis Pharmaceuticals's revenue fell $25.2M (-9%) from $268M in Q2 2026 to $243M in Q3 2026.
Ionis Pharmaceuticals, Q3 2026: revenue $243M (+55% year over year), operating margin -53.8%, net loss $110M, operating cash flow −$179M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $243M | $268M | −$25.2M | -9% |
| Other income, net | $20.6M | −$11.1M | $31.7M | — |
| Income tax benefit | $141K | −$1.3M | $1.4M | — |
| Net loss | $110M | $115M | −$4.7M | -4% |
| Costs & expenses | $373M | $383M | −$9.2M | -2% |
| Operating costs | $373M | $370M | $3.2M | +0.9% |
| Cost of revenue | $3.3M | $2.7M | $583K | +21% |
| SG&A | $154M | $150M | $3.8M | +3% |
| Other operating costs | $216M | $217M | −$1.2M | -0.6% |
| Operating cash sources | $227M | −$516M | $743M | — |
| Depreciation & amortization | $4.3M | $4.1M | $201K | +5% |
| Share-based compensation | $43.4M | $45.6M | −$2.2M | -5% |
| Cash used in operations | $179M | −$566M | $745M | — |
| Net loss absorbed | $110M | $115M | −$4.7M | -4% |
| Working capital & other | $117M | −$630M | $748M | — |
Questions
How much did Ionis Pharmaceuticals's revenue grow quarter over quarter in Q3 2026?
Ionis Pharmaceuticals's revenue fell $25.2M (-9%) from $268M in Q2 2026 to $243M in Q3 2026.